Back to News
Market Impact: 0.15
Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
Source: businesswire.com
Healthcare & BiotechProduct Launches
Johnson & Johnson reported first real-world data for its VARIPULSE Pro Platform and 12-month outcomes for its OMNYPULSE Platform, both used in atrial fibrillation treatment. The article excerpt provides no outcome figures or conclusions, limiting assessment of clinical or market significance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
JNJ0.60
More News
- AI stocks tumble as the defensives rise. What it says about this uneasy market
- Apple’s iPhone Duo Hits Stores in Face of Short Supply and High Demand
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war